PL2084543T3 - Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II - Google Patents

Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II

Info

Publication number
PL2084543T3
PL2084543T3 PL07846265T PL07846265T PL2084543T3 PL 2084543 T3 PL2084543 T3 PL 2084543T3 PL 07846265 T PL07846265 T PL 07846265T PL 07846265 T PL07846265 T PL 07846265T PL 2084543 T3 PL2084543 T3 PL 2084543T3
Authority
PL
Poland
Prior art keywords
provasopressin
neurophysin
fragments
acute coronary
coronary syndrome
Prior art date
Application number
PL07846265T
Other languages
English (en)
Inventor
Andreas Bergmann
Nils Morgenthaler
Jana Papassotiriou
Joachim Struck
L. Ng Leong
Original Assignee
B.R.A.H.M.S Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200610050497 external-priority patent/DE102006050497A1/de
Priority claimed from DE200610057409 external-priority patent/DE102006057409A1/de
Application filed by B.R.A.H.M.S Gmbh filed Critical B.R.A.H.M.S Gmbh
Publication of PL2084543T3 publication Critical patent/PL2084543T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/04Oxytocins; Vasopressins; Related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL07846265T 2006-10-26 2007-10-26 Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II PL2084543T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE200610050497 DE102006050497A1 (de) 2006-10-26 2006-10-26 Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE200610057409 DE102006057409A1 (de) 2006-12-04 2006-12-04 Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
PCT/DE2007/001928 WO2008049422A2 (de) 2006-10-26 2007-10-26 Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii
EP07846265.2A EP2084543B1 (de) 2006-10-26 2007-10-26 Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii

Publications (1)

Publication Number Publication Date
PL2084543T3 true PL2084543T3 (pl) 2018-04-30

Family

ID=39276269

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07846265T PL2084543T3 (pl) 2006-10-26 2007-10-26 Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II

Country Status (8)

Country Link
US (3) US8501485B2 (pl)
EP (1) EP2084543B1 (pl)
JP (2) JP5320294B2 (pl)
DE (1) DE112007003185A5 (pl)
DK (1) DK2084543T3 (pl)
ES (1) ES2652027T3 (pl)
PL (1) PL2084543T3 (pl)
WO (1) WO2008049422A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE602007007595D1 (en) * 2006-04-24 2010-08-19 Univ Wien Med Ten
PL2084543T3 (pl) * 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
ES2724478T3 (es) * 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores
EP3199951B1 (en) * 2008-10-31 2019-11-20 B.R.A.H.M.S GmbH Arginine vasopressin pro-hormone as predicitive biomarker for diabetes
ES2643033T3 (es) * 2009-05-05 2017-11-21 B.R.A.H.M.S Gmbh Estratificación basada en la hormona vasoactiva de los pacientes que sufren de enfermedades relacionadas con la función/disfunción endotelial
RU2618437C2 (ru) * 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
WO2013036913A1 (en) * 2011-09-08 2013-03-14 Nexus Dx, Inc. A multilevel analyte assay
CN108700596A (zh) * 2016-02-01 2018-10-23 普雷西奥公司 用于心血管疾病和事件的诊断和预后方法
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
KR102318236B1 (ko) * 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305142D0 (en) * 1993-03-12 1993-04-28 Medinnova Sf Method
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
EP1539818B1 (en) * 2002-07-16 2010-12-15 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
PL2084543T3 (pl) * 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2148203A1 (en) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophilic granule proteases as markers in cardiological diseases
ES2724478T3 (es) * 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores

Also Published As

Publication number Publication date
DK2084543T3 (en) 2018-01-22
EP2084543B1 (de) 2017-10-18
JP5320294B2 (ja) 2013-10-23
US8501485B2 (en) 2013-08-06
WO2008049422A3 (de) 2009-01-15
US20100028921A1 (en) 2010-02-04
DE112007003185A5 (de) 2009-10-01
US10254289B2 (en) 2019-04-09
US20130344513A1 (en) 2013-12-26
US20160131660A1 (en) 2016-05-12
ES2652027T3 (es) 2018-01-31
HK1137808A1 (en) 2010-08-06
US9261517B2 (en) 2016-02-16
WO2008049422A2 (de) 2008-05-02
EP2084543A2 (de) 2009-08-05
JP2013178249A (ja) 2013-09-09
JP2010507786A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
PL2084543T3 (pl) Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
IL197014A0 (en) Process for the manufacture of snac (salcaprozate sodium)
EP1862003A4 (en) APPLICATION FRAMEWORK FOR PROVIDING A PLURALITY OF CONTENT AND ENABLING INTERACTION THEREWITH IN A TELEVISION ENVIRONMENT
EP2014142A4 (en) DOUBLE PLASMA RADIATION SOURCES AND METHODS
IL210026A0 (en) Serum or plasma microrna as biomarkers for non-small cell lung cancer
PL2320927T3 (pl) Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
GB0905120D0 (en) Buprenorphine-containing non-pressurised spray composition for transmucisal administration
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
EP1871363A4 (en) COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
EP1922345A4 (en) PROCESS FOR THE PREPARATION OF COPOLYMER-1
IL193143A0 (en) Effectof bst2 inhibitor
ZA201006556B (en) Compositions comprising antibodies or antibody fragments
EP2128117A4 (en) MODIFIER FOR EXPLOSIVE SUBSTANCES
PL2019685T3 (pl) Defektywny interferujący wirus
IL187855A0 (en) Processes for the preparation of docetaxel
GB2431974B (en) Insulation coating for pipework
SG128641A1 (en) Ionization modifier for mass spectrometry
GB2437799B (en) Defective interfering virus
GB0404056D0 (en) Inspection chamber system
TWM300601U (en) Thin-nail structure for nailing gun
AU2006906795A0 (en) Structural beams
PL378101A1 (pl) Urządzenie do dostarczania gazu w komorze klimatycznej
GB0619445D0 (en) Defective interfering virus
GB0501202D0 (en) Targets for therapy
PL380143A1 (pl) Mechanizm korekcji spągnic górniczej obudowy zmechanizowanej